Piramal Enterprises’ (PEL) wholly owned Critical Care subsidiary in UK has completed its acquisition of a portfolio of drugs for spasticity and pain management from Mallinckrodt LLC (Mallinckrodt). The acquisition was for a cash consideration of $171 million and up to an additional $32 million payable depending on financial performance of the acquired assets over the next three years.
The portfolio acquired includes Gablofen (baclofen), a severe spasticity management product, which is currently marketed in the United States, and two pain management products, which are currently under development. Gablofen has also been approved for launch in eight European markets. In the twelve months ending September 30, 2016, the acquired portfolio generated revenues of $44.6 million.
Piramal Enterprises is one of India’s large diversified companies, with a presence in Pharmaceuticals, Healthcare Information Management and Financial Services.
| Company Name | CMP |
|---|---|
| Bajaj Finance | 974.60 |
| Shriram Finance | 1012.80 |
| Aditya Birla Capital | 370.00 |
| Chola Invest & Fin. | 1688.90 |
| Tata Capital | 328.80 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: